NASDAQ
47.22USD
+1.07 (+2.32%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.8B
P/E
—
EPS
—
Beta
1.93
52W range
26.61-60.91
Day range
46.21–47.80
Open
47.05
Prev close
46.15
Volume
776.5K
Avg volume
1.2M
Dividend
0.00
IPO
2013-10-29
https://www.zacks.com/stock/news/2965148/veracyte-vcyt-q2-earnings-and-revenues-surpass-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2965148 · 7/30/2026+0.60
https://www.zacks.com/stock/news/2955281/rxsight-rxst-surges-6-1-is-this-an-indication-of-further-gains?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2955281 · 7/17/2026-0.20
https://www.fool.com/coverage/etfs/2026/07/12/biotech-etfs-how-do-fbt-and-ibb-match-up-on-cost-structure-and-performance/ · 7/12/2026+0.00
https://www.fool.com/coverage/filings/2026/07/04/a-veracyte-insider-sold-24-000-company-shares-for-usd1-1-million-here-s-a-deeper-look-at-the-transaction/ · 7/4/2026+0.60
https://www.fool.com/coverage/filings/2026/06/27/what-to-know-about-this-usd197-000-veracyte-insider-sale-after-a-120-stock-rally/ · 6/27/2026
https://www.businesswire.com/news/home/20260519940364/en/Veracyte-to-Participate-in-Upcoming-Investor-Conferences/ · 5/19/2026+0.00
https://www.zacks.com/stock/news/2915388/veracyte-vcyt-beats-q1-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2915388 · 5/6/2026+0.80
https://www.zacks.com/stock/news/2914835/wall-street-analysts-think-veracyte-vcyt-could-surge-39-16-read-this-before-placing-a-bet?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2914835 · 5/5/2026+0.80
https://www.prnewswire.com/news-releases/pinkdx-publishes-groundbreaking-evidence-in-endometrial-cancer-detection-using-a-simple-vaginal-swab-302734634.html · 4/6/2026+0.20
https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2873809 · 2/23/2026+0.00
https://www.zacks.com/stock/news/2826219/here-s-why-veracyte-vcyt-is-a-great-buy-the-bottom-stock-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2826219 · 1/30/2026+0.60
https://www.zacks.com/stock/news/2822876/why-veracyte-vcyt-is-poised-to-beat-earnings-estimates-again?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_7-2822876 · 1/26/2026+1.00
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
